HemCon Medical Technologies Revenue Growth Surges in Japan
WESTPORT, Conn., March 24, 2014 /PRNewswire
HemCon Medical Technologies, Inc. (“HemCon”), a wholly owned subsidiary of TriStar Wellness Solutions(R), Inc. (OTCQB: TWSI) and a leading developer and marketer of advanced medical products, announced today significant sales growth and momentum for the HemCon hemostatic product line in Japan. Sales for the first quarter of 2014 exceed overall sales for the previous year, and are trending to bring significant growth for the remainder of the year. This growth is fueled by new focus on sales and marketing efforts of HemCon’s exclusive partner in Japan, Zeria Pharmaceuticals Ltd. Co. (Zeria), who has worked with the HemCon product line since 2010, ensuring the current and newly developed products become the standard of care for hemostasis in the country. Japan has the third largest global woundcare market, estimated to growth to $2.3B by 2016.
The HemCon products are relevant solutions for the Japanese healthcare needs, with focus on cardiac catheterization, emergency care, woundcare, hemodialysis and oral surgery; HemCon products provide superior bleeding control through their proprietary raw material formulation of chitosan. Innovative and efficacious HemCon products, paired with the specific market intelligence and know-how from Zeria will also ensure the companies continue to improve medical device innovation through exciting new product introductions planned for the upcoming year.
“We are encouraged by the success we have seen in this first quarter,” said William Perrin, HemCon’s Japan Representative, “We are well positioned to continue with a strong sales effort and expect 2014 to be a very momentous year, which puts us in an excellent position to increase the HemCon product offerings in Japan.”
About HemCon Medical Technologies:
HemCon Medical Technologies Inc., founded in 2001, develops, manufactures, and markets innovative technologies for hemostatic devices for the control of bleeding resulting from trauma or surgery. HemCon products are designed for use by military and civilian first responders as well as medical professionals in hospital and clinical settings where control of bleeding are of critical importance. HemCon is headquartered in Portland, Ore. With a 36,000 sq. ft. state of the art manufacturing facility, the Company has additional commercial operations in Ireland and the Czech Republic.
For more information, please visit: www.hemcon.com.
About TriStar Wellness Solutions:
TriStar Wellness Solutions, Inc. (TWSI) is a health and wellness company that targets under-met consumer opportunities in the OTC and professional marketplace. Its core strategy plans to meet the growing demand for personalized, care solutions by leveraging proprietary innovation and healthcare technology with the rapid transformation of the healthcare marketplace to create innovative, science based solutions and brands. TriStar recently acquired HemCon Medical Technologies Inc., a developer, manufacturer, and marketer of innovative technologies for hemostatic devices for the control of bleeding resulting from trauma or surgery. It also owns the Beaute de Maman(TM) brand of women’s health products.
Additional information is available at: www.tstarwellness.com
For more information: prnewswire.com/hemcon-medical-technologies-revenue-growth-surges-in-japan
Disclaimer/ Disclosure: The Investors News Magazine is a third party publisher of news and research as well as creates original content as a news source. Original content created by Investors News Magazine is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site may be compensated by featured companies for news submissions and content marketing. Contact each company directly for press release questions. Disclosure is posted on each release if required but otherwise the news was not compensated for and is published for the sole interest of our readers.